drugset / Trial / NCT04839575
Study of Latiglutenase in T1D/CD Patients
Phase 2
Terminated
13 enrolled
Entero Therapeutics
Immunogenics, LLC · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedCrossoverDouble-blindTreatment
Summary
This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening.
Timeline
- Start
- 2021-04-06
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
Outcome
Outcome not reported
Stopped (Enrollment): “Covid-19 interruptions and enrollment challenges”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Latiglutenase | Protein / enzyme biologic | — | Oral |